Morepen Laboratories Limited has informed the Exchange about Bagging/Receiving of orders/contracts
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories has won a ₹825 crore (USD 91 million) international order from a leading global pharma major. The contract is for CDMO (Contract Development and Manufacturing Organization) services, marking Morepen's entry into the high-growth CDMO segment. Supplies are expected to commence within 4-5 months, with full execution scheduled over 12-15 months from the date of award, subject to standard regulatory and operational approvals. The company has confirmed no promoter group interest in the awarding entity and that this is not a related party transaction. The order represents a significant revenue opportunity and a strategic diversification beyond Morepen's traditional API business.
This is a sizeable export order in hard currency that strengthens the revenue pipeline and marks a strategic move into the CDMO segment, which typically carries higher margins. Positive for the stock in the near term as it validates Morepen's global capabilities and could drive re-rating.